Why was early therapeutic research on psychedelic drugs abandoned?
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Advocates of the therapeutic use of psychedelic drugs have argued that a promising approach to treatment was prematurely abandoned in the 1960s primarily because of Richard Nixon's ‘War on Drugs’. This paper (1) briefly describes research in the 1950s and 1960s in North America on the use of LSD to treat alcohol dependence, anxiety in terminal illness, and anxiety and depression; and (2) discusses the factors that led to its abandonment. Method: An analysis of historical scholarship on psychedelic research in the 1950s, 1960s and 1970s in North America. Results: Research on psychedelic drugs in psychiatry was abandoned for a number of reasons that acted in concert. A major factor was that clinical research on psychedelic drugs was caught up in the tighter regulation of pharmaceutical research after the Thalidomide disaster in 1963. Psychedelic drugs also presented special challenges for randomised, placebo-controlled clinical trials in the 1970s that were not as positive as the claims made by their advocates in the 1950s and 1960s. Clinical research became more difficult after 1965 when Sandoz ceased providing psychedelic drugs for research and their nonmedical use was prohibited in 1970. Conclusions: The demise of psychedelic drug research was not solely due to the ‘War on Drugs’. It was hastened by tighter regulation of pharmaceutical research, the failure of controlled clinical trials to live up to the claims of psychedelic advocates, and the pharmaceutical industry's lack of interest in funding clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706 · cited 1×
“For example, prescribers will be able to use psilocybin off label as a first-line treatment for depression (Carhart-Harris & Goodwin, 2017) and as a treatment for anxiety disorders (Muttoni et al., 2019).”
BackgroundPsychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649 · cited 1×
“…these drugs are used if they are approved to treat depression and PTSD, in light of the encouraging results of phase 2 trials on psilocybin for depression and MDMA for PTSD (Jerome et al., 2020; Luoma, Chwyl, Bathje, Davis, & Lancelotta, 2020; Muttoni, Ardissino, & John, 2019; Reiff et al., 2020).”
BackgroundLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · cited 1×
“Their positive results were not replicated in later controlled trials (Mangini, 1998), a meta-analysis of which found patients given LSD had better outcomes 6 months after treatment but were no better off at 12 months (Krebs & Johansen, 2012).”
ResultJohnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · cited 2×
“The effects of this class of drugs share more of a family resemblance than common pharmacological mechanisms of action (Grinspoon & Bakalar, 1979; Johnson et al., 2019).”
BackgroundMethodConstructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472 · cited 5×
“Second, attempts are being made in the USA to use popular referenda to legalise the adult use of psychedelic mushrooms (Decriminalize Nature, 2020; Peters, 2021; Smith, 2021), the same approach used by advocates after California became the first US state to permit physicians to prescribe cannabis if they ‘deemed [it]…”
BackgroundInfluentialClassical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256 · cited 1×
“For example, prescribers will be able to use psilocybin off label as a first-line treatment for depression (Carhart-Harris & Goodwin, 2017) and as a treatment for anxiety disorders (Muttoni et al., 2019).”
BackgroundThe experimental use of psychedelic (LSD) psychotherapy.
Pahnke, W. N. (1970) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1970.03170240060010 · Cited by 220
A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy
Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1769878 · Cited by 212
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress
Ross, S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1482261 · Cited by 102
Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide
Kast, E. (1967) · The Psychiatric Quarterly · doi:10.1007/bf01575629 · Cited by 94 · cited 1×
“…reported 70% improvement in symptoms in neurotic disorders (e.g. Cohen & Eisner, 1959) and investigators later reported that LSD substantially reduced anxiety and distress in patients who had terminal cancer (e.g. Kast, 1966, 1967; Pahnke, Kurland, Unger, Savage, & Grof, 1970; Ross, 2018).”
Background
Cited by
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115531 · Cited by 134
Therapeutic effect of psilocybin in addiction: A systematic review
van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1134454 · Cited by 127
Is good science leading the way in the therapeutic use of psychedelic drugs?
Hall, W. D., & Humphreys, K. (2022) · Psychological Medicine · doi:10.1017/s0033291722003191 · Cited by 17
“Nor should we accept the argument that psychedelic drugs should be given an easier ride through peer and regulatory review processes because they were treated unfairly in the past, a claim which has arguably been overstated (Hall, 2021b).”
BackgroundSelf-citation
Metadata
- Authors
- Hall, W.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2021-10-21
- Volume
- 52
- Issue
- 1
- Pages
- 26-31
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W3207479206
- Cited by
- 86
- References
- 10
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Why was early therapeutic research on psychedelic drugs abandoned? https://app.cochat.ai/papers/10.1017/s0033291721004207
- The paper
- Hall, W. (2022). Why was early therapeutic research on psychedelic drugs abandoned? Psychological Medicine. https://doi.org/10.1017/s0033291721004207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.